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ABSTRACT
Objective: The objective of this work was to develop and validate a novel, simple, rapid, and reliable analytical method for separation and determination 
of R-isomer impurity in Etodolac bulk drug material by normal-phase high-performance liquid chromatography (HPLC) as per International 
Conference on Harmonization (ICH) guidelines.
Methods: The etodolac R-isomer and S-isomer were separated on a Chiralcel OD-H (150 × 4.0 mm, 5 µm) column using ethanol: n-hexane: 
Trifluoroacetic acid (50:50:0.1 v/v.) mobile phase with equipped detector at wavelength 225 nm and 25°C column oven temperature. The resolution 
between R-isomer and S-isomer was more than two recorded on the chromatogram. The specified method was developed and validated for various 
parameters such as reproducibility, limit of detection (LOD), limit of quantification, linearity and range, robustness, solution stability and mobile 
phase stability according to the ICH guidelines.
Results: Linearity was found for etodolac R-isomer over the concentration range of 600-6000 ng/ml, with the linear regression (correlation coefficient 
R = 0.998) and proved to be robust. LOD and limit of quantification of etodolac R-isomer were found to be 200 and 600 ng/ml. The retention time 
of R-isomer was considered to be 2.8 minutes. The percentage recovery of etodolac R-isomer has been ranged from 97.0 to 102.0 in bulk drug 
material sample. The proposed analytical method has been found to be suitable, precise, reliable and accurate for the separation and quantitative 
determination of etodolac R-isomer in bulk drug sample.
Conclusion: A novel, speedy, accurate, precise, reliable and rugged analytical method have been developed and validated for normal phase HPLC to 
determine R-isomer impurity in etodolac bulk drugs material as per ICH guideline.
Keywords: Etodolac, High performance liquid chromatography, Known impurity, Normal phase, Validation.
INTRODUCTION
Etodolac is used in the treat pain. Etodolac is active pharmaceutical bulk 
drug used in manufacturing of tablet and capsules. It works by reducing 
hormones that cause inflammation and mild to moderate pain in the 
body. In addition to this, it maintains a better physiological regulation 
for secretion of insulin. Etodolac is a racemic mixture of R-isomer and 
S-isomer.
Various types of analytical methods have been reported for qualitative 
and quantitative analysis of etodolac. In the literature enantiomeric 
separation of etodolac by reverse phase chromatography [1], nonsteroidal 
anti-inflammatory drug analysis [2], etodolac efficient method for optical 
resolution [3], bioequivalence of S-etodolac determination [4], and 
optical resolution of the drug by capillary electrophoretic techniques [5]. 
This report describes a normal phase liquid chromatography method 
for the speedy separation of R-isomer and S-isomer of etodolac. The 
developed high-performance liquid chromatography (HPLC) method 
has been validated for quantitative determination of R-isomer in 
etodolac. Etodolac is racemic mixture of (+)S and (−)R-etodolac. Etodolac 
chemically known as 1,8-diethyl-1,3,4,9-tetrahydropyrano [3,4-b]indole-
1-acetic acid, chemical structures show in Fig. 1. (R)-(−)-etodolac show in 
Fig. 2 and (S)-(+)-etodolac show in Fig. 3.
METHODS
Chemicals and reagents
Etodolac, etodolac racemic of R-isomer and S-isomer were kindly 
supplied by Lavender Laboratories Private Limited, Kurkumbh, Pune, 
Maharashtra, India. All the reagents were used of HPLC grade, n-hexane 
purchased from Merck, absolute ethanol purchased from Hayman 
speciality products UK and trifluoroacetic acid purchased from Sigma-
Aldrich.
Instrument specification
LC system of Shimadzu 2010 series with ultraviolet (UV) detector and 
inbuilt auto injector was utilized for method development and validation. 
The data acquisition and system suitability calculation trigger using 
LC solution software. Analytical balance used for weighing, electronic 
balance type 200 Shimadzu corporation Japan. The instrument also 
consists of Chiralcel OD-H column (150 × 4.0 mm, 5 µm).
Chromatographic conditions
Mobile phase (v/v): Ethanol: n-hexane: Trifluoroacetic acid (50:50:0.1). 
Column: Chiralcel OD-H (150 × 4.0 mm, 5 µm). Flow rate was set at 
1.0 ml/minutes. The column oven temperature was maintained at 25°C. 
UV detection was carried out at a wavelength of 225 nm. The injection 
volume was 5 µl. The mobile phase was filtered through a 0.25 mm 
membrane filter and degassed to remove dissolved gases if any.
Preparation of stock solution and sample solution
Racemic etodolac stock solutions (0.1 mg/ml) were prepared by 
dissolving in the mobile phase of an appropriate amount of the 
substances. The working solutions of etodolac S-isomer and R-isomer 
were prepared in mobile phase of an analyte concentration of S-isomer 
was fixed as 0.1 mg/ml.
Validation of developed method
Method reproducibility
Developed method was determined by has been reproduced and 
measuring repeatability by instrument precision and method precision. 
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The intermediate precision performed on different days for retention 
times and peak areas response of R-isomer and S-isomer.
The instrument precision determined on six replicate injections of 
racemic mixture of etodolac. Method repeatability determined on six 
sample injections of a 0.1 mg/ml concentration solution containing 
R-isomer spiked in S-isomer (i.e., of 0.5%) was carried out. Intermediate 
precision was also determined on over a period of day by carrying 
successive six replicate injections per day.
Limit of detection (LOD) and limit of quantification of R-isomer
The LOD, defined as the lowest concentration of analyte that can 
be accepted at detection level on above the baseline signal and not 
required to quantified, the signal was estimated above the baseline as 
three times the signal to noise ratio [6].
The limit of quantitation (LOQ), defined as lowest concentration of 
analyte that can be quantified, reproducible with suitable precision 
and accuracy, the signal was estimated as ten times the signal to noise 
ratio [6]. The LOD and LOQ were achieved by injecting a series of dilute 
solutions of R-isomer.
The developed method has been precise, reliable for determination 
of R-isomer of etodolac at limit of quantification level was checked by 
testing with six test solutions of R-isomer etodolac, which was prepared 
at LOQ level and percentage relative standard deviation (% RSD) 
calculated for area response.
Linearity and range of R-isomer
Linearity for detector response was assessed by on six calibration 
of sample solutions preparation of R-isomer covering range from 
600 ng/ml (LOQ) to 3000 ng/ml (600 ng/ml, 1200 ng/ml, 1800 ng/ml, 
2400 ng/ml, 3000 ng/ml and 6000 ng/ml), solution was prepared in 
mobile phase from R-isomer stock solution.
Obtained regression curve was by plotting peak area response against 
concentration of solution using the least squares method. Linearity was 
performed on three consecutive days of same concentration range from 
the same stock solution. The relative standard deviation in percentage 
of the slope and Y-intercept of the calibration curve was calculated. 
Quantification of R-isomer in bulk sample.
The sample of etodolac was supplied by Lavender Laboratories 
Private Limited showed the presence of R-isomer is 0.10%. Recovery 
experiments and standard addition were conducted to determine the 
accuracy of the present method for the quantification of R-isomer in 
etodolac bulk drug samples.
The study was carried out in triplicate at 0.25, 0.50 and 0.75% of 
targeted analyte concentration of etodolac. The calculated recovery of 
etodolac R-isomer was obtained by calibration curve from the slope and 
Y-intercept.
Robustness
The method robustness of an ability of the method to remain unaffected 
by small change in method parameters, i.e., column oven temperature, 
flow rate, composition of mobile phase. To determine the method 
robustness by experimental conditions were purposely altered and 
checked chromatographic resolution between R-isomer and S-isomer 
of etodolac was evaluated.
The flow rate of mobile phase was 1.0 ml/minutes. To study the impact 
of flow rate on the resolution of isomers, it was changed from 0.8 ml/
minutes to 1.2 ml/minutes by ±0.2 ml/minutes. The effects of change 
in the proportion of ethanol on resolution were studied by varying 
from −1% to +1% and other components of mobile phase were held 
constant as stated in section 2.4. The effect of column oven temperature 
on resolution was changing at 20°C and 30°C instead of 25°C. While the 
mobile phase components and flow rate were held constant as stated.
Solution stability and mobile phase stability
Solution stability of etodolac in solution form of an analyte 
concentration was studied by keeping tightly closed volumetric flask at 
room temperature on work bench in laboratory for 48 hrs. The content 
of etodolac R-isomer was checked for every 6 hrs time interval up to 
the study period.
The stability of mobile phase was carried out by evaluating the content 
of etodolac R-isomer in sample solutions. Freshly prepared samples 
were injected at every 6 hrs time interval for 48 hrs. Same mobile phase 
was used for both of the experiment during the study period.
Specificity and system suitability
The ability to well separate and measure accurately of R-isomer of 
etodolac, specifically in etodolac recemic solution and analyte peak of 
a sample solution. Checked the interference of the blank, standards 
solution with interest of an analyte and test preparation. No interference 
observed corresponding to the analyte peak of a sample solution.
Calculations
×
Area of R-isomer in test 
solution chromatogram% R-Isomer = 100




The aim of the work is a separation and determination of R-isomer and 
S-isomer of etodolac using normal phase HPLC within a very short run 
time. The etodolac chiral analysis is time-consuming by using normal 
phase. The 0.1 mg/ml solution concentration of recemic mixture 
prepared in mobile phase, which was used for the method development. 
To develop a rugged, precise and suitable LC method for the separation 
of etodolac isomer, different mobile phases, and stationary phases 
were employed. In an experiment has been an attempt to separate the 
isomers of etodolac. Various experiments were conducted, to select the 
best stationary and mobile phases that would give suitable resolution 
and selectivity for the two isomers from recemic mixture. There is 
Fig. 1: Chemical structure: 2-(1,8-diethyl-4,9-dihydro-3H-
pyrano[3,4-b]indol-1-yl)acetic acid
Fig. 2: Chemical structure: (R)-(−)-etodolac
Fig. 3: Chemical structure: (S)-(+)-etodolac
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no method in literature using mobile phase composition of ethanol: 
N-hexane: Trifluoroacetic acid (50:50:0.1 v/v) by using Chiralcel OD-H 
column. The chromatographic separation was achieved on a Chiralcel 
OD-H (150 × 4.0 mm, 5 µm) column using a mobile phase system 
containing ethanol: N-hexane: Trifluoroacetic acid (50:50:0.1 v/v).
The flow rate of the mobile phase was 1.0 ml/minutes. At 25°C column 
temperature, the peak shape of etodolac was found symmetrical.
In the developed and validated optimized method, the typical retention 
times of R-isomer and S-isomer of etodolac were about 2.8 and 
3.5 minutes, respectively. The isomeric separation of etodolac is shown 
in Fig. 4. The system suitability test results are tabulated as below 
presented in Table 1.
Table 1: Systemsuitability parameters and report
S. No. Parameter Results
1 Retention time of R-isomer 2.8 minutes
2 Retention time of S-isomer 3.5 minutes
3 Resolution (USP) 2.4
4 *Number of therotical plates of R-isomer 4310
5 *Number of therotical plates of S-isomer 4415
6 Tailing factor (USP) of R-isomer 1.2
7 Tailing factor (USP) of S-isomer 1.1
*Calculated on USP tangent method
Table 2: Validation results of the developed normal phase 
method
S. No. Validation parameter Results
A. Repeatability 
(n=6, % RSD)
1 Retention time of R-isomer 0.4
2 Retention time of S-isomer 0.6
3 Peak area of R-isomer 3.1
4 Peak area of S-isomer 0.7
B. Intermediate pricision 
(n=18, % RSD)
1 Retention time of R-isomer 0.8
2 Retention time of S-isomer 0.5
3 Peak area of R-isomer 3.2
4 Peak area of S-isomer 0.8
C. LOD-LOQ (R-isomer)
1 LOD (ng/ml) 200
2 LOQ (ng/ml) 600
3 Precision at LOQ (% RSD) 2.9
D. Linearity (R-isomer)
1 Calibration range (ng/ml) 600-6000
2 Calibration points 6
3 Correlation coefficient 0.998
% RSD: Percentage relative standard deviation, LOD: Limit of detection, 
LOQ: Limit of quantification
Table 3: Recovery results of R-isomer in bulk drugs
Added (ng) (n=3) Recovered (ng) % Recovery % RSD
1003 977 97.4 2.8
2520 2570 102.0 2.1
3941 3917 99.4 2.0
Table 4: Method robustness
S. No. Parameters USP resolution between 
R-isomer and S-isomer















Fig. 4: Typical chromatogram of system suitability standard solution
Validation results of the method
The % RSD was better than 0.7% for the retention times of the isomers, 
0.9% for etodolac peak area and 4.0% for R-isomer peak area presented 
in Table 2. In the intermediate precision study, results show that values 
of % RSD were in the same manner obtained for repeatability and 
presented in Table 2.
The LOD and LOQ concentrations were determined to be 200 and 
600 ng/ml for R-isomer of etodolac when a signal-to-noise ratio of 3 for 
detection and 10 for quantitation were used as the criteria. The method 
precision for R-isomer of etodolac at the limit of quantification was 
<4% RSD presented in Table 2.
Good linearity was observed for R-isomer of etodolac over the 
concentration range of 600-6000 ng/ml. Linearity was checked for 
R-isomer of etodolac over the same concentration range for 3 
consecutive days. The % RSD for the calibration curve of the 
slope and Y-intercept were 2.2 and 1.4, respectively, presented in 
Table 2.
The recovery experiments and standard addition were conducted 
for R-isomer of etodolac in bulk samples in triplicate at 0.25, 0.50 
and 0.75% of analyte concentration. Recovery was calculated for the 
calibration curve from slope and Y-intercept obtained in linearity study 
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and percentage recovery was ranged from 97.4 to 102.0 presented in 
Table 3.
An HPLC chromatogram of spiked R-isomer at 0.5% level in etodolac 
sample is shown in Fig. 5. The chromatographic resolution of R-isomer 
and S-isomer of etodolac peaks was used to evaluate the method 
robustness under modified conditions. The resolution between 
R-isomer and S-isomer of etodolac was >2.0, under all separation 
conditions tested presented in Table 4.
No significant change in the R-isomer content was observed in etodolac 
sample during experiments of solution stability and mobile phase 
stability. Hence etodolac sample solution and mobile phase are stable 
for at least 48 hrs.
CONCLUSION
A novel, simple, precise, specific, and accurate normal phase liquid 
chromatography method were described for the separation of etodolac 
isomer. The method was completely validated as per International 
Conference on Harmonization guidelines and showing satisfactory 
data for all the tested method validation parameters. The developed 
method can be used for the quantitative determination R-isomer in 
bulk materials.
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